GSK vs. NVS
Compare and contrast key facts about GlaxoSmithKline plc (GSK) and Novartis AG (NVS).
Scroll down to visually compare performance, riskiness, drawdowns, and other indicators and decide which better suits your portfolio: GSK or NVS.
Correlation
The correlation between GSK and NVS is 0.45, which is considered to be moderate. This suggests that the two assets have some degree of positive relationship in their price movements. Moderate correlation can be acceptable for portfolio diversification, offering a balance between risk and potential returns.
Performance
GSK vs. NVS - Performance Comparison
Loading data...
Key characteristics
GSK:
-0.51
NVS:
0.54
GSK:
-0.46
NVS:
1.02
GSK:
0.94
NVS:
1.14
GSK:
-0.42
NVS:
0.67
GSK:
-0.73
NVS:
1.44
GSK:
16.38%
NVS:
9.25%
GSK:
26.98%
NVS:
19.55%
GSK:
-55.21%
NVS:
-41.72%
GSK:
-15.75%
NVS:
-6.63%
Fundamentals
GSK:
$74.41B
NVS:
$215.79B
GSK:
$2.02
NVS:
$6.38
GSK:
18.13
NVS:
17.04
GSK:
0.36
NVS:
1.29
GSK:
2.45
NVS:
4.05
GSK:
3.95
NVS:
5.60
GSK:
$31.53B
NVS:
$52.86B
GSK:
$22.56B
NVS:
$39.86B
GSK:
$8.24B
NVS:
$21.88B
Returns By Period
In the year-to-date period, GSK achieves a 11.71% return, which is significantly lower than NVS's 15.99% return. Over the past 10 years, GSK has underperformed NVS with an annualized return of 2.89%, while NVS has yielded a comparatively higher 6.42% annualized return.
GSK
11.71%
7.88%
5.12%
-13.71%
1.42%
2.89%
NVS
15.99%
1.33%
6.82%
10.55%
10.65%
6.42%
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Risk-Adjusted Performance
GSK vs. NVS — Risk-Adjusted Performance Rank
GSK
NVS
GSK vs. NVS - Risk-Adjusted Performance Comparison
This table presents a comparison of risk-adjusted performance metrics for GlaxoSmithKline plc (GSK) and Novartis AG (NVS). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Loading data...
Dividends
GSK vs. NVS - Dividend Comparison
GSK's dividend yield for the trailing twelve months is around 4.15%, more than NVS's 3.67% yield.
| TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
GSK GlaxoSmithKline plc | 4.15% | 4.60% | 3.75% | 4.78% | 4.92% | 5.49% | 4.28% | 5.55% | 5.72% | 7.06% | 5.96% | 6.09% |
NVS Novartis AG | 3.67% | 3.88% | 3.44% | 3.91% | 4.08% | 3.40% | 2.87% | 3.72% | 3.50% | 4.06% | 3.51% | 3.14% |
Drawdowns
GSK vs. NVS - Drawdown Comparison
The maximum GSK drawdown since its inception was -55.21%, which is greater than NVS's maximum drawdown of -41.72%. Use the drawdown chart below to compare losses from any high point for GSK and NVS. For additional features, visit the drawdowns tool.
Loading data...
Volatility
GSK vs. NVS - Volatility Comparison
GlaxoSmithKline plc (GSK) has a higher volatility of 7.78% compared to Novartis AG (NVS) at 6.86%. This indicates that GSK's price experiences larger fluctuations and is considered to be riskier than NVS based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading data...
Financials
GSK vs. NVS - Financials Comparison
This section allows you to compare key financial metrics between GlaxoSmithKline plc and Novartis AG. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
GSK vs. NVS - Profitability Comparison
GSK - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on May 2025, GlaxoSmithKline plc reported a gross profit of 5.58B and revenue of 7.52B. Therefore, the gross margin over that period was 74.2%.
NVS - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on May 2025, Novartis AG reported a gross profit of 10.39B and revenue of 13.62B. Therefore, the gross margin over that period was 76.3%.
GSK - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on May 2025, GlaxoSmithKline plc reported an operating income of 2.22B and revenue of 7.52B, resulting in an operating margin of 29.5%.
NVS - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on May 2025, Novartis AG reported an operating income of 4.66B and revenue of 13.62B, resulting in an operating margin of 34.2%.
GSK - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on May 2025, GlaxoSmithKline plc reported a net income of 1.62B and revenue of 7.52B, resulting in a net margin of 21.6%.
NVS - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on May 2025, Novartis AG reported a net income of 3.61B and revenue of 13.62B, resulting in a net margin of 26.5%.